Physician profile
David Wing Lee
NPI 1245554138
$4,119.56
in general payments reported to CMS, 2019-2025
17 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.07 · 2020: $77.68 · 2021: $1,872 · 2022: $232 · 2023: $254 · 2024: $652 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,542.78 | 2021 | |
| Organogenesis INC. | $798.85 | 2024-2025 | Apligraf, Puraply Wound Matrix, Simplimax |
| Orthofix Medical, INC. | $411.11 | 2023-2025 | Physio-Stim, Accelstim, Spinal-Stim |
| Horizon Therapeutics Plc | $358.33 | 2021-2023 | Krystexxa |
| Bioventus LLC | $282.18 | 2021-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $173.40 | 2019-2024 | Versajet |
| Impactortho, INC. | $97.84 | 2021 | |
| Amgen INC. | $94.91 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Zimmer Biomet Holdings, INC. | $77.68 | 2020 | |
| Lilly USA, LLC | $76.48 | 2024-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $46.32 | 2019 | |
| Depuy Synthes Sales INC. | $39.26 | 2025 | Motoband |
| Elevate Surgical Co | $35.40 | 2025 | |
| Averitas Pharma INC. | $30.34 | 2024 | Qutenza |
| Tactile Systems Technology INC | $19.64 | 2025 | Nimbl, Flexitouch Plus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $19.06 | 2025 | Activ.A.C., V.A.C. Dermatac, Prevena |
| Vertex Pharmaceuticals Incorporated | $15.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.